Episode Details

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus, influenza and SARS-CoV-2 before discussing revised guidelines for how to treat respiratory viral infection guidelines by the CDC, effectiveness of the new SARS-CoV-2 vaccines and the combination of vaccination and antiviral therapy against the development of disease, continues to dispel the myth of viral rebound, how to pay for paxlovid, the lack of evidence supporting ivermectin as an antiviral drug, when to use steroids and the benefits of convalescent plasma, how COVID-19 affects cognitive function and the effect of long COVID and how healthcare works have difficulty making the proper diagnosis for long COVID even using a questionnaire.

Become a patron of TWiV!

• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Variant hospital admissions (CDC)
• What to do when you are sick with a respiratory virus (CDC)
• Basis for respiratory virus guidance (CDC)
• Effectiveness of updated COVID-19 vaccines (MMWR)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Synergy or additive protection with vaccination and oral antivirals (CID)
• To rebound or to not rebound (MMWR)
• Know your COVID-19 tools (ESMED)
• How to pay for Paxlovid (PAXCESS)
• Molnupiravir safety and efficacy (JMV)
• Still talking about Ivermectin? (Jou